Showing 6581-6590 of 7112 results for "".
- DermTech Announces New Websitehttps://practicaldermatology.com/news/dermtech-announces-new-website/2458796/DermTech, Inc., a privately held commercial stage molecular diagnostic company developing gene expression tests for skin cancer, announced the release of its new website (www.dermtech.com), designed to provide education and inf
- Study Finds Increasing Prices for Prescription Dermatology Drugs Since 2009https://practicaldermatology.com/news/study-finds-increasing-prices-for-prescription-dermatology-drugs-since-2009/2458800/A recent study published in JAMA Dermatology found that the price of prescription dermatologic drugs rose considerably from 2009 to 2015, with the vast majority of price increases occurring after 2011. In an effo
- Brickell Secures Rights to a Novel Class of RORγ Inhibitors for Psoriasis and Other Autoimmune Diseaseshttps://practicaldermatology.com/news/brickell-biotech-secures-rights-to-a-novel-class-of-ror-inhibitors-for-psoriasis-and-other-autoimmune-diseases/2458801/Brickell Biotech, Inc. has secured the exclusive world-wide rights to a series of novel retinoic acid–related orphan nuclear receptor gamma (RORy) inhibitors from Orca Pharmaceuticals (Orca) and New York University (NYU). This chemical series is based on intellectual property emerg
- Pfizer and Allergan to Combinehttps://practicaldermatology.com/news/pfizer-and-allergan-to-combine/2458803/The boards of directors for Pfizer Inc. and Allergan plc have both unanimously approved, and the companies have entered into, a definitive merger agreement under which Pfizer will combine with Allergan in a stock transaction currently valued at $363.63 per Allergan share, for a total enterprise v
- Almirall Acquires Veltin® and Altabax® from Stiefel, a GSK Companyhttps://practicaldermatology.com/news/almirall-acquires-veltin-and-altabax-from-stiefel-a-gsk-company/2458802/Almirall has acquired the rights to Veltin® and Altabax, from Stiefel, a GSK company, in exchange for distribution rights to Toctino® and an undisclosed cash payment.
- Ortek Therapeutics Files Patent Applications for New Microbiome to Reduce S. Aureus Proliferationhttps://practicaldermatology.com/news/ortek-therapeutics-files-patent-applications-for-new-microbiome-to-reduce-s-aureus-proliferation/2458808/Stony Brook University and Ortek Therapeutics, Inc. filed two patent applications in the United States and internationally for nutrient based compositions utilizing innovative microbiome technology. Developed at Stony Brook University, these compositions have been exclusively licensed to Ortek as
- AMA Calls for Ban on Direct to Consumer Advertising of Prescription Drugs and Medical Deviceshttps://practicaldermatology.com/news/ama-calls-for-ban-on-direct-to-consumer-advertising-of-prescription-drugs-and-medical-devices/2458806/Physicians at the Interim Meeting of the American Medical Association (AMA) adopted new policy aimed at driving solutions to make prescription drugs more affordable. Physicians cited concerns that a growing proliferation of ads is driving demand for expensive treatments despite the clinic
- ASDS Awards 10 Clinical Research Grantshttps://practicaldermatology.com/news/asds-awards-10-clinical-research-grants/2458811/The American Society for Dermatologic Surgery (ASDS) has awarded a total of $96,000 to 10 new clinical research projects through its Cutting Edge Research Grant program. This year’s research projects will focus on topics ranging from examining the effectiveness of specific lasers on surgica
- Immune Pharmaceuticals: FDA Accepts IND Application for Bertilimumab for Bullous Pemphigoidhttps://practicaldermatology.com/news/immune-pharmaceuticals-fda-accepts-ind-application-for-bertilimumab-for-bullous-pemphigoid/2458813/Immune Pharmaceuticals, Inc. has indicated that the FDA has accepted the Company's Investigational New Drug (IND) application for its first in class, lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP). This FDA acceptance enables the Company to expand recruitme
- Dermatologist Harold Lancer and Ryan Seacrest Collaborate on Male Skincare Linehttps://practicaldermatology.com/news/dermatologist-harold-lancer-and-ryan-seacrest-collaborate-on-male-skincare-line/2458814/Dr. Harold Lancer and radio personality, television host and producer Ryan Seacrest have revealed an exclusive partnership in the burgeoning men's grooming category. They plan to launch a men's skincare line late in 2016. This pairing combines Dr. Lan